INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.400
-0.070 (-4.76%)
Apr 28, 2026, 4:00 PM EDT - Market closed
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
$2,381
Profits / Employee
-$2,187,286
Market Cap
37.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Actinium Pharmaceuticals | 25 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
INMB News
- 4 weeks ago - INmune Bio Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - INmune Bio Inc. Announces 2025 Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - GlobeNewsWire
- 2 months ago - INmune Bio Transcript: Study update - Transcripts
- 2 months ago - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar - GlobeNewsWire
- 2 months ago - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - GlobeNewsWire
- 2 months ago - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - GlobeNewsWire
- 3 months ago - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - GlobeNewsWire